Merck & Co (NYSE: MRK) has announced results from the KEYNOTE-966 trial of Keytruda (pembrolizumab) alongside chemotherapy (gemcitabine and cisplatin) for the first-line treatment of patients with advanced or unresectable biliary tract cancer (BTC).
Results from the Phase III trial showed that the Keytruda regimen demonstrated a statistically-significant and clinically-meaningful improvement in overall survival (OS) compared to chemotherapy alone.
"Adding Keytruda to chemotherapy holds the potential to extend life"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze